StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ – Free Report) in a research report report published on Saturday. The brokerage issued a hold rating on the medical research company’s stock.
Enzo Biochem Price Performance
Shares of NYSE:ENZ opened at $0.47 on Friday. Enzo Biochem has a 52 week low of $0.41 and a 52 week high of $1.30. The company’s 50 day moving average is $0.57 and its two-hundred day moving average is $0.87.
Enzo Biochem (NYSE:ENZ – Get Free Report) last posted its earnings results on Monday, March 17th. The medical research company reported ($0.02) EPS for the quarter. Enzo Biochem had a negative net margin of 75.34% and a negative return on equity of 7.96%.
Institutional Inflows and Outflows
About Enzo Biochem
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
See Also
- Five stocks we like better than Enzo Biochem
- Short Selling: How to Short a Stock
- Can TikTok Stock Picks Really Make You Rich?
- Why Invest in High-Yield Dividend Stocks?
- The “Quality” Rotation: Back to Basics Investing
- How to Evaluate a Stock Before Buying
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.